ATXI — AVENUE THERAPEUTICS, INC.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1644963 ·
Last close
$0.26
Market Cap
$848.8K
52W High
$0.52
52W Low
$0.25
ADV30
3,199
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -707,000 | -690,000 | 1,976,000 | 1,942,000 | 1,407,000 |
| Mar 2026 | 0 | — | -714,000 | -695,000 | 2,468,000 | 2,417,000 | 1,270,000 |
| Dec 2025 | 0 | — | -955,000 | -709,000 | 2,931,000 | 2,855,000 | 1,099,000 |
| Sep 2025 | 0 | — | -724,000 | -683,000 | 3,725,000 | 3,709,000 | 1,422,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,085,000
Investing CF
$0
Financing CF
$0
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-106,184,000
Inventory
—
Receivables
$800,000
ST Investments
—
EBIT TTM
$-2,096,000
Pretax Income TTM
$-1,784,000
Interest Exp TTM
$0
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
—
Free Cash Flow
$-631,500
Enterprise Value
$-1,093,216
Total Cash
$1,942,000
Total Debt
$0
Shares Out
3,294,967
Trailing EPS
$-0.86
Book Value
$0.17
ROE
-164.8%
ROA
-63.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,404,000 | -3,286,000 | -2,909,000 | 2,931,000 | 1,099,000 | — | -1,833,000 |
| Dec 2024 | 0 | -11,283,000 | -11,652,000 | 2,672,000 | 816,000 | — | -9,026,000 |
| Dec 2023 | 0 | -14,540,000 | -10,377,000 | 1,850,000 | 1,196,000 | — | -9,451,000 |
| Dec 2022 | 0 | -8,043,000 | -3,552,000 | 6,845,000 | 3,579,000 | — | -7,596,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.14
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. | $805.5K | $0.10 | — |
| EVFM | Evofem Biosciences, Inc. | $927.7K | $0.01 | — |
| SKVI | SKINVISIBLE, INC. | $972.7K | $0.18 | — |
| VBIO | Valion Bio, Inc. | $689.1K | $0.17 | — |
| BDRX | Biodexa Pharmaceuticals Plc | $1.08M | $1.20 | — |
News headlines (Yahoo Finance, 1h cache)
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
2026-02-23 13:00 · Yahoo
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
2025-11-06 12:00 · Yahoo
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
2025-11-06 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.